Related Experiment Videos
A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial
1Department of Viral Oncology, Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan.
Abstract:
Cleidocranial dysplasia (CCD), an autosomal-dominant human bone disease, is thought to be caused by heterozygous mutations in runt-related gene 2 (RUNX2)/polyomavirus enhancer binding protein 2alphaA (PEBP2alphaA)/core-binding factor A1 (CBFA1). To understand the mechanism underlying the pathogenesis of CCD, we studied a novel mutant of RUNX2, CCDalphaA376, originally identified in a CCD patient. The nonsense mutation, which resulted in a truncated RUNX2 protein, severely impaired RUNX2 transactivation activity. We show that signal transducers of transforming growth factor beta superfamily receptors, Smads, interact with RUNX2 in vivo and in vitro and enhance the transactivation ability of this factor. The truncated RUNX2 protein failed to interact with and respond to Smads and was unable to induce the osteoblast-like phenotype in C2C12 myoblasts on stimulation by bone morphogenetic protein. Therefore, the pathogenesis of CCD may be related to the impaired Smad signaling of transforming growth factor beta/bone morphogenetic protein pathways that target the activity of RUNX2 during bone formation.
Insights
Cleidocranial dysplasia (CCD) is a bone disease linked to RUNX2 mutations. A new RUNX2 mutant impairs Smad signaling, crucial for bone formation, suggesting a pathway for CCD development.
Area of Science:
- Genetics
- Molecular Biology
- Developmental Biology
Background:
- Cleidocranial dysplasia (CCD) is an autosomal-dominant skeletal disorder.
- Heterozygous mutations in the runt-related gene 2 (RUNX2) are implicated in CCD pathogenesis.
- RUNX2, also known as PEBP2αA or CBFA1, is a key transcription factor in bone development.
Purpose of the Study:
- To investigate the functional consequences of a novel RUNX2 mutation (CCDαA376) found in a CCD patient.
- To elucidate the interaction between RUNX2 and Smad signaling pathways in bone formation.
- To understand the molecular mechanisms underlying CCD pathogenesis.
Main Methods:
- Studied a novel RUNX2 mutant (CCDαA376) from a CCD patient.
- Assessed RUNX2 transactivation activity and its interaction with Smads in vitro and in vivo.
- Utilized C2C12 myoblasts to evaluate the osteoblast-like phenotype induction upon bone morphogenetic protein stimulation.
Main Results:
- The CCDαA376 mutation resulted in a truncated RUNX2 protein with severely impaired transactivation activity.
- Signal transducers and activators of transcription (Smads) interact with RUNX2 and enhance its transactivation.
- The truncated RUNX2 failed to interact with Smads and could not induce osteoblast differentiation, indicating a disruption in transforming growth factor beta/bone morphogenetic protein signaling.
Conclusions:
- The pathogenesis of Cleidocranial dysplasia may involve impaired Smad signaling in transforming growth factor beta/bone morphogenetic protein pathways.
- RUNX2 activity during bone formation is critically dependent on its interaction with Smad proteins.
- Defective RUNX2-Smad interaction due to mutations like CCDαA376 contributes to the skeletal abnormalities seen in CCD.